Spiritus Mundi PLC (LSE:SPMU) — Market Cap & Net Worth
Market Cap & Net Worth: Spiritus Mundi PLC (SPMU)
Spiritus Mundi PLC (LSE:SPMU) has a market capitalization of $224.94 (GBX1.85 Million) as of June 18, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31763 globally and #1319 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Spiritus Mundi PLC's stock price GBX0.04 by its total outstanding shares 49300000 (49.30 Million). Review Spiritus Mundi PLC total liabilities to assess the company's total debt and financial obligations.
Spiritus Mundi PLC Market Cap History: 2022 to 2025
Spiritus Mundi PLC's market capitalization history from 2022 to 2025. Data shows change from $16.50K to $224.94 (-76.69% CAGR).
Spiritus Mundi PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Spiritus Mundi PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SPMU by Market Capitalization
Companies near Spiritus Mundi PLC in the global market cap rankings as of June 18, 2026.
Key companies related to Spiritus Mundi PLC by market ranking:
- Twenty One Capital, Inc. (NYSE:XXI): Ranked #6197 globally with a market cap of $2.08 Billion USD.
- Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ:DMII): Ranked #11178 globally with a market cap of $642.10 Million USD.
- Ares Acquisition Corporation II (NYSE:AACT): Ranked #11615 globally with a market cap of $587.05 Million USD.
- HCM II Acquisition Corp. Unit (NASDAQ:HONDU): Ranked #12180 globally with a market cap of $525.00 Million USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #6197 | Twenty One Capital, Inc. | NYSE:XXI | $2.08 Billion | $6.00 |
| #11178 | Drugs Made In America Acquisition II Corp. Ordinary Shares | NASDAQ:DMII | $642.10 Million | $10.08 |
| #11615 | Ares Acquisition Corporation II | NYSE:AACT | $587.05 Million | $9.49 |
| #12180 | HCM II Acquisition Corp. Unit | NASDAQ:HONDU | $525.00 Million | $21.00 |
Spiritus Mundi PLC Historical Marketcap From 2022 to 2025
Between 2022 and today, Spiritus Mundi PLC's market cap moved from $16.50K to $ 224.94, with a yearly change of -76.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | GBX224.94 | -99.00% |
| 2024 | GBX22.49K | 0.00% |
| 2023 | GBX22.49K | +36.36% |
| 2022 | GBX16.50K | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Spiritus Mundi PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $224.94 USD |
| MoneyControl | $224.94 USD |
| MarketWatch | $224.94 USD |
| marketcap.company | $224.94 USD |
| Reuters | $224.94 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Spiritus Mundi PLC
Spiritus Mundi Plc does not have significant operations. It focuses on acquisition opportunities in the clinical diagnostics sector, including clinical laboratory services, clinical diagnostics, and healthcare IT platforms in Europe and Asia. The company was incorporated in 2021 and is based in London, the United Kingdom.